Nisa Investment Advisors LLC Has $42,000 Stock Position in Surmodics, Inc. (NASDAQ:SRDX)

Nisa Investment Advisors LLC lessened its holdings in shares of Surmodics, Inc. (NASDAQ:SRDX) by 98.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,093 shares of the company’s stock after selling 67,336 shares during the period. Nisa Investment Advisors LLC’s holdings in Surmodics were worth $42,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of SRDX. SG Americas Securities LLC increased its stake in shares of Surmodics by 14.7% in the first quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock valued at $151,000 after buying an additional 660 shares during the period. Lazard Asset Management LLC lifted its position in shares of Surmodics by 13.4% in the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock worth $166,000 after purchasing an additional 673 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Surmodics by 7.5% in the 1st quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock valued at $202,000 after purchasing an additional 481 shares during the last quarter. Hardin Capital Partners LLC acquired a new stake in shares of Surmodics during the second quarter worth $206,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Surmodics in the second quarter valued at $229,000. Institutional investors own 96.63% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. StockNews.com assumed coverage on Surmodics in a research note on Thursday. They issued a “hold” rating on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $50.00.

Surmodics Price Performance

SRDX stock opened at $38.46 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.98. The business has a 50-day simple moving average of $38.57 and a two-hundred day simple moving average of $38.69. The company has a market capitalization of $548.82 million, a P/E ratio of -47.48 and a beta of 1.20. Surmodics, Inc. has a 52-week low of $25.17 and a 52-week high of $42.44.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).